Tests zilovertamab vedotin with standard chemotherapy for previously untreated diffuse large B-cell lymphoma
Tests zilovertamab vedotin with standard chemotherapy in adults with untreated diffuse large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Key facts
- Where
- Albany, Alexandria, Ann Arbor, Athens, Belleville, Bethesda, Billings, Bridgeton, Charlottesville, Cincinnati, Clermont, Columbia, Dallas, Detroit, Eugene, Fargo, Fort Wayne, Fullerton, Gilbert, Golden, Grand Rapids, Greenville, Hampton, Hialeah, Hinsdale, Houston, Jackson, Kansas City, Knoxville, Las Vegas, Lexington, Long Beach, Los Alamitos, Los Angeles, Louisville, Lubbock, Madison, Mobile, Naperville, Nashville, New York, O'Fallon, Ocoee, Olympia, Orange City, Owensboro, Phoenix, Portland, Reno, Richmond, Roanoke, Saginaw, San Francisco, Shirley, Sioux Falls, Springfield, Tampa, The Woodlands, Topeka, and Tucson, United StatesSee the 64 sites
- Phase
- Phase 3
Where in United States
- New York Oncology Hematology, P.C. (Site 0129)Albany, United StatesTaking people
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care (Site 0184)Alexandria, United StatesTaking people
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor (Site 9545)Ann Arbor, United StatesTaking people
- University Cancer & Blood Center, LLC (Site 0141)Athens, United StatesTaking people
- New Jersey Cancer Care (Site 7002)Belleville, United StatesTaking people
- American Oncology Partners, P.A. (Site 0185)Bethesda, United StatesTaking people
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana (Site 0178)Billings, United StatesTaking people
- Circuit Clinical - SSM Health Cancer Care DePaul (Site 0166)Bridgeton, United StatesTaking people
- University of Virginia Cancer Center (Site 0138)Charlottesville, United StatesTaking people
- Oncology_Hematology Care Clinical Trials, LLC (OHC) (Site 8002)Cincinnati, United StatesTaking people
- Clermont Oncology Center (Site 0182)Clermont, United StatesTaking people
- Maryland Oncology Hematology (MOH) (Site 8004)Columbia, United StatesTaking people
- University of Missouri Hospital (Site 0175)Columbia, United StatesTaking people
- Texas Oncology - DFW (Site 8000)Dallas, United StatesTaking people
- Karmanos Cancer Institute (Site 0174)Detroit, United StatesTaking people
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) (Site 8001)Eugene, United StatesTaking people
- Sanford Health Roger Maris Cancer Center (Site 0189)Fargo, United StatesTaking people
- Fort Wayne Medical Oncology and Hematology (Site 0149)Fort Wayne, United StatesTaking people
- Providence Medical Foundation-Oncology (Site 0168)Fullerton, United StatesTaking people
- Banner MD Anderson Cancer Center (Site 0165)Gilbert, United StatesTaking people
- Lutheran Hospital - Cancer Centers of Colorado (Site 0180)Golden, United StatesTaking people
- Corewell Health (Site 0130)Grand Rapids, United StatesTaking people
- East Carolina University (Site 0159)Greenville, United StatesTaking people
- Prisma Health - Upstate (Site 0158)Greenville, United StatesTaking people
- Virginia Oncology Associates (VOA) (Site 8005)Hampton, United StatesTaking people
- Bioresearch Partner (Site 0157)Hialeah, United StatesTaking people
- Hope and Healing Cancer Services (Site 9511)Hinsdale, United StatesTaking people
- Houston Methodist Cancer Center (Site 0154)Houston, United StatesTaking people
- Center for Oncology and Blood Disorders (Site 0153)Houston, United StatesNo longer taking part
- The University of Mississippi Medical Center (Site 0161)Jackson, United StatesTaking people
- Truman Medical Center (Site 0122)Kansas City, United StatesTaking people
- The University of Tennessee Medical Center (Site 0142)Knoxville, United StatesTaking people
- Comprehensive Cancer Centers of Nevada (Site 0113)Las Vegas, United StatesTaking people
- OptumCare Cancer Care (Site 0121)Las Vegas, United StatesTaking people
- University of Kentucky (Site 0106)Lexington, United StatesTaking people
- MemorialCare Health System - Long Beach Medical Center (Site 9559)Long Beach, United StatesTaking people
- Cancer Blood and Specialty Clinic (Site 0109)Los Alamitos, United StatesTaking people
- Cedars-Sinai Medical Center (Site 0115)Los Angeles, United StatesTaking people
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews (Site 0163)Louisville, United StatesTaking people
- Joe Arrington Cancer Research and Treatment Center (Site 0183)Lubbock, United StatesTaking people
- SSM Health Dean Medical Group (Site 0140)Madison, United StatesTaking people
- USA Mitchell Cancer Institute (Site 0173)Mobile, United StatesTaking people
- Edward Cancer Center (Site 0197)Naperville, United StatesTaking people
- SCRI Oncology Partners (Site 7000)Nashville, United StatesTaking people
- Icahn School of Medicine at Mount Sinai (Site 0164)New York, United StatesTaking people
- Cancer Care Specialists of Illinois (Site 0152)O'Fallon, United StatesTaking people
- Orlando Health Cancer Institute (Site 0169)Ocoee, United StatesTaking people
- Vista Oncology (Site 4201)Olympia, United StatesTaking people
- Mid Florida Hematology and Oncology Center (Site 0172)Orange City, United StatesTaking people
- Owensboro Medical Health System (Site 0195)Owensboro, United StatesTaking people
- Banner MD Anderson Cancer Center - University Medical Center Phoenix (Site 0167)Phoenix, United StatesTaking people
- Kaiser Permanente Interstate Medical Office - Central (Site 0181)Portland, United StatesTaking people
- Cancer Care Specialists (Site 9582)Reno, United StatesTaking people
- Virginia Cancer Institute (Site 0148)Richmond, United StatesTaking people
- Blue Ridge Cancer Care (Site 0132)Roanoke, United StatesTaking people
- Central Michigan University - Saginaw (Site 0198)Saginaw, United StatesTaking people
- Pacific Hematology Oncology Associates (Site 0131)San Francisco, United StatesTaking people
- New York Cancer and Blood Specialists (Site 9000)Shirley, United StatesTaking people
- Sanford Cancer Center (Site 0143)Sioux Falls, United StatesTaking people
- Oncology and Hematology Associates (Site 9546)Springfield, United StatesTaking people
- Tampa General Hospital (Site 0134)Tampa, United StatesTaking people
- Texas Oncology-The Woodlands (Site 8003)The Woodlands, United StatesTaking people
- Cotton O'Neil Cancer Center (Site 0108)Topeka, United StatesNo longer taking part
- The University of Arizona Cancer Center - North Campus (Site 0124)Tucson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06717347EU 2024-515566-13-00
- Record updated
- 10 November 2026
- Original description
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.Read full original descriptionShow less
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Inclusion: Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues; Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale; Has received no prior treatment for their DLBCL; Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization; Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA); Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART); Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization; Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
Exclusion: Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma; Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication; Has ongoing corticosteroid therapy; Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed; Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection; Has a history of transformation of indolent disease to DLBCL; Has a demyelinating form of Charcot-Marie-Tooth disease; HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Known additional malignancy that is progressing or has required active treatment within the past 2 years; Has active autoimmune disease that has required systemic treatment in the past 2 years; Has active infection requiring systemic therapy; Has history of allogeneic tissue/solid organ transplant; Has Ann Arbor Stage I DLBCL; Has clinically significant pericardial or pleural effusion; Has ongoing Grade >1 peripheral neuropathy; Known active central nervous system (CNS) lymphoma.